Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria.
| Autor: | Glincher R; Departments of Pediatrics., Lentini-Rivera A; Departments of Pediatrics., Andre Jones L; Departments of Pediatrics., D'Andrea L; Departments of Pediatrics., Durney C; Departments of Pediatrics., Kasper C; Departments of Pediatrics., Lin Y; Departments of Pediatrics., Shrager L; Departments of Pediatrics., Markova A; Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Lacouture M; Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Modak S; Departments of Pediatrics. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2024 Oct 01; Vol. 46 (7), pp. e531-e533. Date of Electronic Publication: 2024 Aug 22. |
| DOI: | 10.1097/MPH.0000000000002939 |
| Abstrakt: | Outcomes for high-risk neuroblastoma have improved with the addition of antidisialoganglioside (GD2) antibody-mediated immunotherapy to multimodality therapy. Urticaria is an expected side effect of anti-GD2 immunotherapy. Rarely, despite maximal use of antihistamines and H2 receptor antagonists, refractory urticaria can result in impaired quality of life, and delays or discontinuation of immunotherapy. The anti-IgE monoclonal antibody, omalizumab, is approved for the treatment of asthma and chronic spontaneous urticaria. We successfully managed grade 3, naxitamab-related urticaria refractory to standard management in 2 patients using omalizumab, allowing for continued anti-GD2 immunotherapy. Omalizumab did not impact antitumor activity or immunogenicity of naxitamab. Competing Interests: M.L. declares consulting roles with Novartis. S.M. declares consulting roles with Ymabs Therapeutics, US WorldMeds, EUSA Pharma, and Innervate RP Inc. The remaining authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|